Genentech rejects fresh Roche bid
Wednesday 25 February 2009
Pharmaceuticals The Swiss giant Roche was rebuffed yesterday in its $42bn (£29bn) hostile bid to buy the shares it does not already own in the US biotech group Genentech.
The Genentech board advised shareholders to reject the $86.50-a-share bid for 44 per cent of the group, saying that the offer undervalued the company, which specialises in biotherapeutics.
The bid revises an offer of $89 a share, or $44bn, for the minority stake last year, which was also dismissed by Genentech directors as being inadequate. Genentech's bankers have indicated $112 a share as a fair price.
- 1 What happens to your body when you give up sugar?
- 2 Have sex with your iPad thanks to the new sex toy no-one asked for
- 3 The 'sex selfie stick' lets you FaceTime the inside of a vagina
- 4 Why you're almost certainly more like your father than your mother
- 5 Westboro Baptist Church couldn't picket Leonard Nimoy's funeral because they didn't know where it was
Durham Free School: 'Creationism taught at' free school facing closure
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
End of the licence fee: BBC to back radical overhaul of how it is funded
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
Ex-head of MI6: 'We shouldn't kid ourselves that Russia is on a path to democracy'
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
iJobs Money & Business
£8 per hour: Recruitment Genius: This Pension Specialist was established early...
£30 - 35k + Bonus & Benefits: Guru Careers: We are seeking an Executive Assist...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
Voluntary post, reasonable expenses reimbursed: Reach Volunteering: Would you ...